Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression

The high incidence of resistance to Tyrosine Kinase Inhibitors (TKIs) targeted against EGFR and downstream pathways has increased the necessity to identify agents that may be combined with these therapies to provide a sustained response for breast cancer patients. Here, we investigate the therapeuti...

Full description

Saved in:
Bibliographic Details
Published in:J Cancer
Main Authors: Suárez-Arroyo, Ivette J., Rios-Fuller, Tiffany J., Feliz-Mosquea, Yismeilin R., Lacourt-Ventura, Mercedes, Leal-Alviarez, Daniel J., Maldonado-Martinez, Gerónimo, Cubano, Luis A., Martínez-Montemayor, Michelle M.
Format: Artigo
Language:Inglês
Published: Ivyspring International Publisher 2016
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4780125/
https://ncbi.nlm.nih.gov/pubmed/26958085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.13599
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items